Factors influencing patients' acceptance and adherence to active surveillance

Journal of the National Cancer Institute - Monographs

Volumn , Issue 45, 2012, Pages 207-212

  Penson, David F ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BRACHYTHERAPY; CANCER CONTROL; CANCER EPIDEMIOLOGY; CANCER LOCALIZATION; CANCER RISK; CANCER SURGERY; CONCEPTUAL FRAMEWORK; CONSERVATIVE TREATMENT; EXTERNAL BEAM RADIOTHERAPY; HUMAN; MEDICAL DECISION MAKING; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; THEORETICAL MODEL; TREATMENT OUTCOME; BLOOD; DECISION MAKING; DECISION SUPPORT SYSTEM; DOCTOR PATIENT RELATION; MALE; PATIENT PARTICIPATION; PROSTATE TUMOR; SOCIAL SUPPORT; WATCHFUL WAITING;

PROSTATE SPECIFIC ANTIGEN;

DECISION MAKING; DECISION SUPPORT TECHNIQUES; HUMANS; MALE; PATIENT COMPLIANCE; PATIENT PARTICIPATION; PHYSICIAN-PATIENT RELATIONS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SOCIAL SUPPORT; WATCHFUL WAITING;

EID: 84871756820     PISSN: 10526773     EISSN: 17456614     Source Type: Book Series    
DOI: 10.1093/jncimonographs/lgs024     Document Type: Article

References (40)

1. Mohler JL. The 2010 NCCN clinical practice guidelines in oncology on prostate cancer. J Natl Compr Canc Netw. 2010;8(2):145.
2. Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177(6):2106-2131.
3. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010;28(7):1117-1123.
4. Harlan LC, Potosky A, Gilliland FD, et al. Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J Natl Cancer Inst. 2001;93(24):1864-1871.
5. Zeliadt SB, Ramsey SD, Penson DF, et al. Why do men choose one treatment over another? A review of patient decision making for localized prostate cancer. Cancer. 2006;106(9):1865-1874.
6. Shafir E, Tversky A. Thinking through uncertainty: nonconsequential reasoning and choice. Cogn Psychol. 1992;24(4):449-474.
7. Steginga SK, Occhipinti S. The application of the heuristic-systematic processing model to treatment decision making about prostate cancer. Med Decis Making. 2004;24(6):573-583.
8. Bohner G, Moskowitz GB, Chaiken S. The interplay of heuristic and systematic processing of social information. Eur Rev Social Psychol. 1995;6(1):33-68.
9. Feldman-Stewart D, Brundage MD, Van Manen L, Svenson O. Patient-focussed decision-making in early-stage prostate cancer: insights from a cognitively based decision aid. Health Expect. 2004;7(2):126-141.
10. Feldman-Stewart D, Brundage MD, Hayter C, et al. What questions do patients with curable prostate cancer want answered? Med Decis Making. 2000;20(1):7-19.
11. Anandadas CN, Clarke NW, Davidson SE, et al. Early prostate cancer- which treatment do men prefer and why? BJU Int. 2011;107(11):1762-1768.
12. Holmboe ES, Concato J. Treatment decisions for localized prostate cancer: asking men what's important. J Gen Intern Med. 2000;15(10):694-701.
13. Sidana A, Hernandez DJ, Feng Z, et al. Treatment decision-making for localized prostate cancer: what younger men choose and why. Prostate. 2012;72(1):58-64.
14. Davison BJ, Oliffe JL, Pickles T, Mroz L. Factors influencing men undertaking active surveillance for the management of low-risk prostate cancer. Oncol Nurs Forum. 2009;36(1):89-96.
15. van den Bergh RC, van Vugt HA, Korfage IJ, et al. Disease insight and treatment perception of men on active surveillance for early prostate cancer. BJU Int. 2010;105(3):322-328.
16. Gorin MA, Soloway CT, Eldefrawy A, Soloway MS. Factors that influence patient enrollment in active surveillance for low-risk prostate cancer. Urology. 2011;77(3):588-591.
17. Chapple A, Ziebland S, Shepperd S, Miller R, Herxheimer A, McPherson A. Why men with prostate cancer want wider access to prostate specific antigen testing: qualitative study. BMJ. 2002;325(7367):737.
18. Diefenbach MA, Dorsey J, Uzzo RG, et al. Decision-making strategies for patients with localized prostate cancer. Semin Urol Oncol. 2002;20(1):55-62.
19. Davison BJ, Goldenberg SL. Patient acceptance of active surveillance as a treatment option for low-risk prostate cancer. BJU Int. 2011;108(11):1787-1793.
20. Davison BJ, Goldenberg SL. Decisional regret and quality of life after participating in medical decision-making for early-stage prostate cancer. BJU Int. 2003;91(1):14-17.
21. Pickles T, Ruether JD, Weir L, Carlson L, Jakulj F. Psychosocial barriers to active surveillance for the management of early prostate cancer and a strategy for increased acceptance. BJU Int. 2007;100(3):544-551.
22. Ramsey SD, Zeliadt SB, Fedorenko CR, et al. Patient preferences and urologist recommendations among local-stage prostate cancer patients who present for initial consultation and second opinions. World J Urol. 2011;29(1):3-9.
23. Feldman-Stewart D, Brundage MD, Hayter C, Davidson JR, Groome P, Nickel JC. What the prostate cancer patient should know: variations in urologists' opinions. Can J Urol. 1997;4(4):438-444.
24. Zeliadt SB, Penson DF, Moinpour CM, et al. Provider and partner interactions in the treatment decision-making process for newly diagnosed localized prostate cancer. BJU Int. 2011;108(6):851-857.
25. Srirangam SJ, Pearson E, Grose C, Brown SC, Collins GN, O'Reilly PH. Partner's influence on patient preference for treatment in early prostate cancer. BJU Int. 2003;92(4):365-369.
26. Volk RJ, Cantor SB, Cass AR, Spann SJ, Weller SC, Krahn MD. Preferences of husbands and wives for outcomes of prostate cancer screening and treatment. J Gen Intern Med. 2004;19(4):339-348.
27. Carter HB, Kettermann A, Warlick C, et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol. 2007;178(6):2359-2365.
28. Klotz L. Active surveillance for prostate cancer: for whom? J Clin Oncol. 2005;23(32):8165-8169.
29. Martin RM, Gunnell D, Hamdy F, Neal D, Lane A, Donovan J. Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era. J Urol. 2006;176(2):439-449.
30. Bailey DE Jr, Wallace M, Mishel MH. Watching, waiting and uncertainty in prostate cancer. J Clin Nurs. 2007;16(4):734-741.
31. Galbraith ME, Ramirez JM, Pedro LW. Quality of life, health outcomes, and identity for patients with prostate cancer in five different treatment groups. Oncol Nurs Forum. 2001;28(3):551-560.
32. Hedestig O, Sandman PO, Widmark A. Living with untreated localized prostate cancer: a qualitative analysis of patient narratives. Cancer Nurs. 2003;26(1):55-60.
33. van den Bergh RC, Essink-Bot ML, Roobol MJ, et al. Anxiety and distress during active surveillance for early prostate cancer. Cancer. 2009;115(7):3868-3878.
34. van den Bergh RC, Korfage IJ, Borsboom GJ, Steyerberg EW, Essink-Bot ML. Prostate cancer-specific anxiety in Dutch patients on active surveillance: validation of the memorial anxiety scale for prostate cancer. Qual Life Res. 2009;18(8):1061-1066.
35. Steginga SK, Occhipinti S, Gardiner RA, Yaxley J, Heathcote P. Prospective study of men's psychological and decision-related adjustment after treatment for localized prostate cancer. Urology. 2004;63(4):751-756.
36. Mishel MH, Germino BB, Belyea M, et al. Moderators of an uncertainty management intervention: for men with localized prostate cancer. Nurs Res. 2003;52(2):89-97.
37. Oliffe JL, Davison BJ, Pickles T, Mroz L. The self-management of uncertainty among men undertaking active surveillance for low-risk prostate cancer. Qual Health Res. 2009;19(4):432-443.
38. Katz D, Koppie TM, Wu D, et al. Sociodemographic characteristics and health related quality of life in men attending prostate cancer support groups. J Urol. 2002;168(5):2092-2096.
39. Chapple A, Ziebland S, Herxheimer A, McPherson A, Shepperd S, Miller R. Is 'watchful waiting' a real choice for men with prostate cancer? A qualitative study. BJU Int. 2002;90(3):257-264.
40. Kazer MW, Bailey DE Jr, Colberg J, Kelly WK, Carroll P. The needs for men undergoing active surveillance (AS) for prostate cancer: results of a focus group study. J Clin Nurs. 2011;20(3-4):581-586.